Nurix Therapeutics Inc (NRIX NASDAQ) stock market data APIs
$9.1992
0.28(3%)
as of October 14, 2025
Try our APIs with
free plan!
Nurix Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase 1A clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1A clinical trials to treat immuno-oncology indications. It is also developing NX 0479/GS 6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
Prev. Close
9.1992
Open
9.482
High
9.759
Low
9.0534
52 wk Range
8.18-29.56
Market Cap
750 M
Shares Outstanding
76 883 K
Revenue
83 687 K
EPS
-1.03
Beta
2.337
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Nurix Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Nurix Therapeutics Inc data using free add-ons & libraries
Get Nurix Therapeutics Inc Fundamental Data
Nurix Therapeutics Inc Fundamental data includes:
- Net Revenue: 83 687 K
- EBITDA: -259 359 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-09
- EPS/Forecast: -0.8296
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Nurix Therapeutics Inc News
New
How Investors Are Reacting To Gilead Sciences (GILD) Extending Biktarvy Exclusivity and Advancing HIV, Oncology Pipeline
In recent days, Gilead Sciences announced a series of developments, including settlement agreements that extend Biktarvy's U.S. exclusivity to 2036 and updates on innovative therapies in HIV preventio...
Stocks Tumble as Chinese Trade Tensions Resurface
The S&P 500 Index ($SPX) (SPY) today is down -0.80%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -0.88%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -1.89%. December E-mini S&P futu...
Stocks Climb as Dovish Fed Comments Knock Bond Yields Lower
The S&P 500 Index ($SPX) (SPY) today is up +0.32%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.52%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.30%. December E-mini S&P futures (E...
Stocks Tumble as Chinese Trade Tensions Resurface
The S&P 500 Index ($SPX [https://www.barchart.com/futures/quotes/$SPX/overview]) (SPY [https://www.barchart.com/etfs-funds/quotes/SPY/overview]) today is down -0.80%, the Dow Jones Industrials Index...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
